Daniel is a proven leader of life science companies with more than 30 years of experience steering strategy, finance and operations across all stages of the corporate life cycle. He has served as a CFO, strategic consultant and board member to dozens of life science companies ranging from start-ups to publicly traded companies with $2+ billion market capitalizations. He has also been a board member and chairman of audit and compensation committees of both public and private life science companies, including Alcobra, Elicio Therapeutics and Windtree Therapeutics.
Daniel holds a BS from The Wharton School, University of Pennsylvania, and MBA from Harvard Business School.
- Raised more than $2 billion in equity and debt securities for life science companies
- As CFO of Transkaryotic Therapies, negotiated and closed five equity transactions totaling $600 million, including the largest private placement in biotechnology history at the time
- Led development of organizational infrastructures, including recruitment of senior executives, functional managers and scientists for high-growth global companies